|
If you suffered losses in DermTech stock, contact DermTech stock loss lawyer Timothy L. Miles about a DermTech class action lawsuit
SUMMARY OF THIS DERMTECK INVESTOR SYNOPSIS
Welcome to this investor synopsis of the DermTech class action lawsuit. In this synopsis, we will take a hard look at DermTech including its background, leadership, directors, stock information, and then delve into the DermTech class action lawsuit, including the lead plaintiff process, qualifications for the DermTech class action lawsuit, how a DermTech Stock Loss Lawyer can help you, and much more.
We hope you find this information useful and helpful. If you are thinking of moving for lead plaintiff status in the DermTech class action lawsuit, or have any questions about you rights as a class member or anything else, please do not hesitate to reach out to Timothy L. Miles. This will most likely be the only call you need to make. (855) 846–6529 or [email protected]. And, the call is free and so is the fee unless we win or settle your case. BACKGROUND TO DERMTECHOverview of DermTech
Headquartered in San Diego, California, DermTech, Inc. is a molecular diagnostic company that specializes in the development and marketing of novel non-invasive genomics tests. These tests are designed to help diagnose and manage skin conditions, such as skin cancer and inflammatory diseases, found in the United States. DMT, a non-invasive enhancement of melanoma detection, and Smart Sticker, a non-invasive sample collection method, are two of the company's products they offer. In addition, DermTech provides research services and technology platforms on a contract basis, as well as gene expression assays and custom gene assays for pharmaceutical companies. Finally, the company sells its products to pathology and oncology practitioners.
Leadership at DermTech
DermTech is run by a leadership group headed by Bret Christensen, the company's President, Chief Executive Officer (CEO), and a director since May 2023. Prior to joining DermTech, Mr. Christensen was the Chief Commercial Officer of Insulet from May 2017 to May 2023 where he oversaw sales growth from approximately $367 million to $1.1 billion. Other senior leaders are Kevin Sun, Chief Financial Officer, Secretary and Treasurer, Ray Akhavan, General Counsel and Claudia lbarra, Chief Operating Office.
Other executives include Mark Aguillard, Chief Commercial Officer, Loren Clark, M.D. , Chief Medical Officer,` Burkhard Jansel, Chief Medical Affairs Officer; Bill Zonder Chief Information Officer, Daniell Visage, Senior Vice President, Payer Access and Steven Stone, Ph.D. Senior Vice President, Research & Development. DermTech's Board of Directors
The company has a seven-person Board consisting of the following:
The Board of Directors has three standing committees. An Audit Committee, a Compensation Committee, and a Nominating Committee composed of the following directors. Audit Committee Mark Capone Cynthia Collins Herm Rosenman (Chairperson) Compensation Committee Dr. Kirk Malloy Dr. Kirk Malloy Matt Posard (Chairperson) Nominating Committee Cynthia Collins (Chairperson) Nathalie Gerschtein Matt Posard DermTech's Stock Performance
DermTech's common stock trades on NASDAQ and currently trades at approximately $1.50 per share with a 52-Week Range of 1.47 to 6.44. The Company has a market capitalization of $49.845 million, an Average Volume of 241, 732 and a one-year target estimate of 4.70. The Company's income sheet shows a loss in gross profit of $813,000 with a Basis EPs of -3.89.
introduction to the DERMTECH CLASS ACTION LAWSUIT
The DermTech class action lawsuit seeks to represent purchasers or acquirers of DermTech, Inc. (NASDAQ: DMTK) securities between May 3, 2022 and November 3, 2022, inclusive (the “Class Period”). Captioned Bagheri v. DermTech, Inc., No. 23-cv-01885 (S.D. Cal.), the DermTech class action lawsuit charges DermTech and certain of its top current and former executive officers with violations of the Securities Exchange Act of 1934.
If you suffered losses in DermTech stock and wish to serve as lead plaintiff in the DermTech class action lawsuit, please contact DermTech Stock Loss Lawyer Timothy L. Miles by calling 855/846-6529 or via e-mail at [email protected] or by submitting a contact form. Lead plaintiff motions for the DermTech class action lawsuit must be filed with the court no later than December 15, 2023. the To ALLEGATIONS IN THE DERMTECH CLASS ACTION LAWSUITAdd Text
DermTech is a molecular diagnostic company that develops and markets non-invasive genomics test to aid the diagnosis and management of skin cancer, inflammatory skin diseases, and aging-related skin conditions. The DermTech Melanoma Test (“DMT”) is a commercial test offered to assess pigmented skin lesions for melanoma.
The DermTech class action lawsuit alleges that defendants throughout the Class Period failed to disclose that: (i) DermTech experienced challenges with collections from commercial payors; (ii) as a result, there was a lower average selling price for DermTech’s DMT; and (iii) consequently, DermTech’s revenue growth would be adversely impacted. The DermTech class action lawsuit further alleges that on August 8, 2022, DermTech announced its second quarter 2022 financial results and revealed that DermTech expected “a lower average selling price (ASP) for [its] DMT,” due to “Medicare billing code edits . . . as well as less favorable collection patterns from commercial payors.” The complaint alleges that on this news DermTech’s stock price fell approximately 34%. The DermTech class action lawsuit also alleges that on November 3, 2022, DermTech announced its third quarter 2022 financial results, reporting that billable sample volume “sequential growth was flat due to headwinds caused by limited commercial payer coverage.” The DermTech class action lawsuit alleges that DermTech attributed the disappointing growth to “commercial payer collection challenges [have] affect[ed] estimating ASP [average selling price]” and that, as a result, DermTech expected “at least $13 million in assay revenue for the full-year 2022,” which is “below [its] previous guidance range.” The DermTech class action lawsuit alleges that on this news DermTech’s stock price fell by nearly 45%. THE LEAD PLAINTIFF PROCESS IN THE DERMTECH CLASS ACTION LAWSUIT
The Private Securities Litigation Reform Act of 1995 permits any investor who purchased and suffered losses in DermTech stock to seek appointment as lead plaintiff in the DermTech class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class.
A lead plaintiff acts on behalf of all other class members in directing the class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the securities class action lawsuit. An investor’s ability to share in any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff. If you suffered losses in DermTech stock and have further questions, contact DermTech stock loss Lawyer Timothy L. Miles today who will fight to recover your damages in a DermTech class action lawsuit if you suffered losses in DermTech stock. THE BENEFITS OF SERVING AS LEAD PLAINTIFF IN THE DERMTECH CLASS ACTION LAWSUIT
Serving as a Lead Plaintiff in the DermTech class action lawsuit has several advantages and important benefits including:
Thus, there are numerous benefits and other advantages to serving as lead plaintiff in a DermTech class action lawsuit if you suffered losses in DermTech stock. CAN I BE APPOINTED LEAD PLAINTIFF IN THE DERMTECH CLASS ACTION LAWSUIT IF I PURCHASED SHARES OUTSIDE OF THE CLASS PERIOD?
No. Even if you suffered losses in DermTech stock, if you purchased securities outside of the Class period, you will not be able to participate in the DermTech class action lawsuit.
THE LEAD PLAINTIFFS will not GET MORE MONEY THAN CLASS MEMBERS IF THE DERMTECH CLASS ACTION LAWSUIT
However, but they may be entitled to recover their reasonable expenses incurred with are directly related to representing the class in the DermTech class action lawsuit. Under the Private Securities Litigation Reform Act of 1995, a Lead Plaintiff is only entitled to his or her pro rata share of any recovery and does not receive any additional money for serving as a representative party on behalf of the class. However, a court, in its discretion, may approve an award of “reasonable costs and expenses (including lost wages)” to a Lead Plaintiff that directly relates to the representation of the class in the DermTech class action lawsuit on behalf of investors who suffered losses in DermTech stock.
CLASS PERIOD DETERMination IN THE DERMTECH CLASS ACTION LAWSUIT
In a securities fraud class action, the class period refers to a period of time in which it is alleged the price of the company’s stock was artificially inflated due to false and misleading statements made by company executives. The class period starts when the company makes an untrue statement of material fact about the company or fails to disclose a material fact necessary to render other statements not misleading. The class period ends when the truth is revealed to the investing public through a corrective disclosure.
In order to be a part of the class in the DermTech class action lawsuit, you must have suffered losses in DermTech stock by purchasing during the class period when it is alleged the price of the stock was artificially inflated to be included in the DermTech class action lawsuit. A DERMTECH STOCK LOSS LAWYER can HELP you
A DermTech stock loss Lawyer is well-versed in the complex laws that govern the securities industry and litigation and focuses on representing individual investors or funds who have been the victims of fraud or who have disputes with investment professionals. Ordinary individual investors, including civil servants, teachers, nurses, and retirees, may need a securities lawyer. In most cases, they have lost money due to mistakes, incompetence, or fraud by an investment professional.
While FINRA, the SEC, and state securities regulators serve a vital role in protecting investors, they simply have too many individuals, firms, and market transactions to monitor to discover every act of fraud or negligence. Individual investors should consult with a securities lawyer if they have lost money due to fraud or stockbroker misconduct. Look for a securities lawyer with experience, high ethical standards, verifiable credentials, and a trustworthy reputation among his peers and the judiciary, as well as testimonials from previous clients and awards and recognitions. One name that immediately pops up is nationally known and widely respected Nashville lawyer Timothy L. Miles, who has valuable experience and has received numerous awards, mostly due to his high ethical standards, and hard work ethic, including most recently being named a Top 25 Class action lawyer by the National Trial Lawyers Association, and has maintained an AV rating from Martindale-Hubble since 2014, was named a 2023 Top Rated Litigator and 2023 Top Rated Lawyer by Martindale-Hubble and ALM, and was recently named a 2023 Elite Lawyer of the South by Martindale-Hubble for the fifth year in a row, and was a recipient of Avvo Client’s Choice Award in 2021, in 2022 was featured in the Top 100 Lawyers Magazine and received the Lifetime Achievement Award by Premier Lawyers of America (2019–2021). This will most likely be the only call you need to make. (855) 846–6529 or [email protected]. CONTACT A DERMTECH STOCK LOSS LAWYER TODAY IF YOU SUFFERED LOSSES IN DERMTECH STOCK ABOUT A DERMTECH CLASS ACTION LAWSUIT
If you suffered losses in DermTech stock, contact DermTech stock loss lawyer Timothy L. Miles today for a free case evaluation about a DermTech class action lawsuit. Call today and see what a DermTech stock loss lawyer could do for you if you suffered losses in DermTech stock. This will most likely be the only call you need to make. (855) 846–6529 or [email protected].
DermTech stock loss lawyer Timothy L. MilesNashville attorney Timothy L. Miles is a nationally recognized shareholder rights attorney raised in Nashville, Tennessee. Mr. Miles has dedicated his career to representing shareholders, employees, and consumers in complex class-action litigation. Whether serving as lead, co-lead, or liaison counsel, Mr. Miles has helped recover hundreds of millions of dollars for defrauded investors, shaped precedent-setting decisions, and delivered real corporate governance reforms. Judges and peers have repeatedly recognized Mr. Miles relentless advocacy for the underdog, as well as his unbendable ethical standards. Mr. Miles was recently selected by Martindale-Hubbell® and ALM as a 2022 Top Ranked Lawyer, 2022 Top Rated Litigator. and a 2022 Elite Lawyer of the South. Mr. Miles also maintains the AV Preeminent Rating by Martindale-Hubbell®, their highest rating for both legal ability and ethics. Mr. Miles is a member of the prestigious Top 100 Civil Plaintiff Trial Lawyers: The National Trial Lawyers Association, 6Class Action: Class Action: Top National Trial Lawyers, National Trial Lawyers Association (2023), a superb rated attorney by Avvo, a recipient of the Lifetime Achievement Award by Premier Lawyers of America (2019) and recognized as a Distinguished Lawyer, Recognizing Excellence in Securities Law, by Lawyers of Distinction (2019); a Top Rated Litigator by Martindale-Hubbell® and ALM (2019-2022); America's Most Honored Lawyers 2020; Top 1% by America's Most Honored (2020-2022). Mr. Miles has published over sixty articles on various issues of the law, including class actions, whistleblower cases, products liability, civil procedure, derivative actions, corporate takeover litigation, corporate formation, mass torts, dangerous drugs, and more. Please visit our website or call for free anytime. Comments are closed.
|
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
July 2024
Categories
All
|
|
CONTACT
The Law Offices of Timothy L. Miles Tapestry at Brentwood Town Center 300 Centerview Dr., #247 Brentwood, TN 37027 Phone: (855) 846-6529 Email: [email protected] HOURS OF OPERATION Mon-Fri: 24/7 Sat-Sun: 24/7 |
RSS Feed